Table 1 Baseline characteristics

From: Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies

Characteristics

Overall (N = 56)

Age

 Median (range), years

58 (32–76)

Age stratification, n (%)

 \(<\)60 years

32 (57.1)

 \(\ge\)60 years

24 (42.9)

Gender, n (%)

 Male

34 (60.7)

 Female

22 (39.3)

TNM stage, n (%)

 Stage IV

56 (100)

ECOG PS, n (%)

 0

15 (26.8)

 1

41 (73.2)

Metastatic disease, n (%)

 Lung

44 (78.6)

 Liver

34 (60.7)

 Bone

12 (21.4)

 Brain

2 (3.6)

 Adrenal

2 (3.6)

Smoking history, n (%)

 Never

37 (66.1)

 Current

4 (7.1)

 Former

14 (25.0)

 Unknown

1 (1.8)

Prior lines of treatment, n (%)

 0

1 (1.8)

 1

21 (37.5)

 2

15 (26.8)

 ≥3

19 (33.9)

Prior treatment, n (%)

 5-Fluorouracil

55 (98.2)

 Oxaliplatin

48 (85.7)

 Irinotecan

41 (73.2)

  1. ECGO PS Eastern Cooperative Oncology Group Performance Status, TNM tumour, node, and metastasis
Back to article page